163 research outputs found
Procedures for estimating site accessibility and appraisal of implications of site accessibility
High Impact Of Human Leukocyte Antigen Matching On Overall Survival And Transplant Related Mortality In Allogeneic Hematopoietic Stem Cell Transplantation For CLL: Long-Term Study From The EBMT Registry
Age-adjusted recipient pretransplantation telomere length and treatment-related mortality after hematopoietic stem cell transplantation
Telomere attrition induces cell senescence and apoptosis. We hypothesized that age-adjusted pretransplantation telomere length might predict treatment-related mortality (TRM) after hematopoietic stem cell transplantation (HSCT). Between 2000 and 2005, 178 consecutive patients underwent HSCT from HLA-identical sibling donors after myeloablative conditioning regimens, mainly for hematologic malignancies (n = 153). Blood lymphocytes' telomere length was measured by real-time quantitative PCR before HSCT. Age-adjusted pretransplantation telomere lengths were analyzed for correlation with clinical outcomes. After age adjustment, patients' telomere-length distribution was similar among all 4 quartiles except for disease stage. There was no correlation between telomere length and engraftment, GVHD, or relapse. The overall survival was 62% at 5 years (95% confidence interval [CI], 54-70). After a median follow-up of 51 months (range, 1-121 months), 43 patients died because of TRM. The TRM rate inversely correlated with telomere length. TRM in patients in the first (lowest telomere length) quartile was significantly higher than in patients with longer telomeres (P = .017). In multivariate analysis, recipients' age (hazard ratio, 1.1; 95% CI, .0-1.1; P = .0001) and age-adjusted telomere length (hazard ratio, 0.4; 95% CI; 0.2-0.8; P = .01) were independently associated with TRM. In conclusion, age-adjusted recipients' telomere length is an independent biologic marker of TRM after HSCT. (Blood. 2012;120(16):3353-3359)National Institutes of Health Intramural Research Program, National Heart, Lung, and Blood InstituteAA and Myelodysplastic Syndrome International FoundationFrance HPNFAPES
Infectious diseases in allogeneic haematopoietic stem cell transplantation: prevention and prophylaxis strategy guidelines 2016
Place de l'imatinib dans le traitement de la leucémie myéloïde chronique (LMC) en rechute après allogreffe de cellules souches hématopoïétiques
PARIS6-Bibl.Pitié-Salpêtrie (751132101) / SudocPARIS-BIUM (751062103) / SudocSudocFranceF
Surveillance par spirométrie à domicile des complications pulmonaires non infectieuses tardives post allogreffe de cellules souches hématopoïétiques
PARIS7-Xavier Bichat (751182101) / SudocSudocFranceF
Allogreffes 9-10, 10-10 et sang placentaire (devenir de 355 patients traités à l'hôpital Saint-Louis de 2000 à 2011)
CHATENAY M.-PARIS 11-BU Pharma. (920192101) / SudocSudocFranceF
Fertility preservation before an ABVD protocol: no new evidence to support changing the recommendations
Procedures for Estimating Site Accesibility and Appraisal of Implications of Site Accesibility
- …